explore -WSS

explore

author：knowledge 2025-09-06 02:15:31 - browse：873

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： People with substance use disorder deserve online privacy

entertainment

WSS

Key House panel plots a new health care package

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Startup Neumora takes a novel depression drug to Phase 3

AI can’t replace a physician’s gut feeling

FDA panel to weigh safety of artificial wombs for preterm births

Covid’s new normal has set in amid another rise in cases

focus

explore

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

State Dept. review finds Biden bears some blame for Afghanistan failures

PBMs drew scrutiny in House hearing — and so did pharma

Virginia high school admissions case could be legal follow

As digital health tech proliferates, a new institute aims to cut through hype

Medicare proposal to cover medical devices draws a mixed reaction

Free Covid tests will again be offered to all U.S. households

As demand for Covid shots wanes, Moderna seeks its next success

How dance can help nurses traumatized by Covid

explore

At Orexo, a ‘turning point’ for everything but digital health

Medicare has a new plan to address drug shortages

Custom gene therapy hints at new path for rare disease treatments

Key House panel plots a new health care package

Free Covid tests will again be offered to all U.S. households

Listen: Wegovy in the brain & pivotal Alzheimer's data

knowledge

leisure time

entertainment

Wikipedia